GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LUMOSA THERAPEUTICS CO LTD (ROCO:6535) » Definitions » Cyclically Adjusted PS Ratio

LUMOSA THERAPEUTICS CO (ROCO:6535) Cyclically Adjusted PS Ratio : 437.74 (As of Jun. 19, 2024)


View and export this data going back to 2015. Start your Free Trial

What is LUMOSA THERAPEUTICS CO Cyclically Adjusted PS Ratio?

As of today (2024-06-19), LUMOSA THERAPEUTICS CO's current share price is NT$232.00. LUMOSA THERAPEUTICS CO's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was NT$0.53. LUMOSA THERAPEUTICS CO's Cyclically Adjusted PS Ratio for today is 437.74.

The historical rank and industry rank for LUMOSA THERAPEUTICS CO's Cyclically Adjusted PS Ratio or its related term are showing as below:

ROCO:6535' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 128.7   Med: 327.55   Max: 372.64
Current: 356.78

During the past years, LUMOSA THERAPEUTICS CO's highest Cyclically Adjusted PS Ratio was 372.64. The lowest was 128.70. And the median was 327.55.

ROCO:6535's Cyclically Adjusted PS Ratio is ranked worse than
98.61% of 505 companies
in the Biotechnology industry
Industry Median: 5.29 vs ROCO:6535: 356.78

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

LUMOSA THERAPEUTICS CO's adjusted revenue per share data for the three months ended in Mar. 2024 was NT$0.027. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is NT$0.53 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


LUMOSA THERAPEUTICS CO Cyclically Adjusted PS Ratio Historical Data

The historical data trend for LUMOSA THERAPEUTICS CO's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LUMOSA THERAPEUTICS CO Cyclically Adjusted PS Ratio Chart

LUMOSA THERAPEUTICS CO Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 127.65

LUMOSA THERAPEUTICS CO Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 127.65 336.07

Competitive Comparison of LUMOSA THERAPEUTICS CO's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, LUMOSA THERAPEUTICS CO's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LUMOSA THERAPEUTICS CO's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LUMOSA THERAPEUTICS CO's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where LUMOSA THERAPEUTICS CO's Cyclically Adjusted PS Ratio falls into.



LUMOSA THERAPEUTICS CO Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

LUMOSA THERAPEUTICS CO's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=232.00/0.53
=437.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LUMOSA THERAPEUTICS CO's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, LUMOSA THERAPEUTICS CO's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.027/131.7762*131.7762
=0.027

Current CPI (Mar. 2024) = 131.7762.

LUMOSA THERAPEUTICS CO Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201312 0.000 98.326 0.000
201406 0.000 100.560 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.113 99.792 0.149
201603 0.000 100.470 0.000
201606 0.145 101.688 0.188
201609 0.000 101.861 0.000
201612 0.003 101.863 0.004
201703 0.265 102.862 0.339
201706 0.048 103.349 0.061
201709 0.026 104.136 0.033
201712 0.032 104.011 0.041
201803 0.094 105.290 0.118
201806 0.001 106.317 0.001
201809 0.349 106.507 0.432
201812 0.172 105.998 0.214
201903 0.062 107.251 0.076
201906 0.019 108.070 0.023
201909 0.019 108.329 0.023
201912 1.359 108.420 1.652
202003 0.019 108.902 0.023
202006 0.037 108.767 0.045
202009 0.012 109.815 0.014
202012 0.105 109.897 0.126
202103 0.016 111.754 0.019
202106 0.029 114.631 0.033
202109 0.004 115.734 0.005
202112 0.066 117.630 0.074
202203 0.017 121.301 0.018
202206 0.030 125.017 0.032
202209 0.028 125.227 0.029
202212 0.088 125.222 0.093
202303 0.049 127.348 0.051
202306 0.087 128.729 0.089
202309 0.100 129.860 0.101
202312 0.114 129.419 0.116
202403 0.027 131.776 0.027

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


LUMOSA THERAPEUTICS CO  (ROCO:6535) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


LUMOSA THERAPEUTICS CO Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of LUMOSA THERAPEUTICS CO's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


LUMOSA THERAPEUTICS CO (ROCO:6535) Business Description

Traded in Other Exchanges
N/A
Address
Yuanyuan Street, 4th Floor, No. 3-2, Nangang District, Taipei, TWN, 11503
LUMOSA THERAPEUTICS CO LTD develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of CNS, oncology, and inflammatory diseases. Geographically, it derives a majority of its revenue from Asia and also has a presence in Taiwan and America. Its product portfolio includes LT - 1001 and LT - 3001 for Analgesic Injection and Novel Small Molecules for the Treatment of Acute Ischemic Stroke.

LUMOSA THERAPEUTICS CO (ROCO:6535) Headlines

No Headlines